Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Retained Earnings for 17 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 4.89% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (up 4.89% YoY), while the FY2025 annual figure was $30000.0, up 100.0% from the prior year.
• Retained Earnings advanced to $2.2 billion in Q1 2026 per LXRX's latest filing, from $30000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $2.2 billion in Q1 2026 and bottomed at -$2.0 billion in Q4 2024.
• Historically, Retained Earnings has averaged $336.7 million across 5 years, with a median of $30000.0 in 2025.
• On a YoY basis, Retained Earnings climbed as much as 17091540.0% in 2022 and fell as far as 30716680.0% in 2022.
• Lexicon Pharmaceuticals' Retained Earnings stood at $1.7 billion in 2022, then rose by 8.98% to $1.9 billion in 2023, then sank by 205.62% to -$2.0 billion in 2024, then soared by 100.0% to $30000.0 in 2025, then jumped by 7413316.67% to $2.2 billion in 2026.
• Business Quant data shows LXRX's Retained Earnings at $2.2 billion in Q1 2026, $30000.0 in Q4 2025, and $2.1 billion in Q3 2025.